Should I buy or sell Cullinan Oncology stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cullinan Oncology in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGEM shares. View CGEM analyst ratings or view top-rated stocks .

What is Cullinan Oncology's stock price target for 2024?

6 Wall Street analysts have issued 12 month target prices for Cullinan Oncology's shares. Their CGEM share price targets range from $26.00 to $30.00. On average, they predict the company's share price to reach $28.75 in the next year. This suggests a possible upside of 83.9% from the stock's current price. View analysts price targets for CGEM or view top-rated stocks among Wall Street analysts .

How have CGEM shares performed in 2024?

Cullinan Oncology's stock was trading at $10.19 on January 1st, 2024. Since then, CGEM shares have increased by 53.4% and is now trading at $15.63. View the best growth stocks for 2024 here .

Are investors shorting Cullinan Oncology?

Cullinan Oncology saw a increase in short interest in March. As of March 31st, there was short interest totaling 1,440,000 shares, an increase of 53.9% from the March 15th total of 935,400 shares. Based on an average trading volume of 423,600 shares, the days-to-cover ratio is presently 3.4 days. Currently, 5.5% of the company's stock are short sold. View Cullinan Oncology's Short Interest .

When is Cullinan Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CGEM earnings forecast .

How were Cullinan Oncology's earnings last quarter?

Cullinan Oncology, Inc. (NASDAQ:CGEM) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.96) by $0.42.

What ETFs hold Cullinan Oncology's stock?

ETFs with the largest weight of Cullinan Oncology (NASDAQ:CGEM) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) , Range Cancer Therapeutics ETF (CNCR) , Loncar China Biopharma ETF (CHNA) , Tema Oncology ETF (CANC) and First Trust Dow Jones Select Microcap Index Fund (FDM) . IQ Chaikin U.S. Small Cap ETF (CSML) .

When did Cullinan Oncology IPO?

Cullinan Oncology (CGEM) raised $149 million in an initial public offering (IPO) on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

How do I buy shares of Cullinan Oncology?

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CGEM

Cullinan Oncology (CGEM) Stock Price, News & Analysis

→ [Shocking] Elon Musk’s Plan To End Banks (From Crypto 101 Media) (Ad)

Free CGEM Stock Alerts

$15.63

-0.03 (-0.19%)

(As of 04/22/2024 ET)

Compare

Today's Range: $15.29
▼
$16.32
50-Day Range: $15.32
▼
$18.51
52-Week Range: $7.64
▼
$20.62

Volume: 953,675 shs
Average Volume: 475,444 shs
Market Capitalization: $673.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $28.75

Get Cullinan Oncology alerts:

Cullinan Oncology MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 83.9% Upside
$28.75 Price Target
Short Interest: Bearish
5.49% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.55
Based on 49 Articles This Week
Insider Trading: Selling Shares
$1.21 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.21) to ($3.03) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.22 out of 5 stars

Medical Sector

310th out of 909 stocks

Biological Products, Except Diagnostic Industry

42nd out of 154 stocks

4.5

Analyst's Opinion

Consensus Rating
Cullinan Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Cullinan Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
5.49% of the float of Cullinan Oncology has been sold short.
Short Interest Ratio / Days to Cover
Cullinan Oncology has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Cullinan Oncology has recently increased by 53.94%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cullinan Oncology does not currently pay a dividend.
Dividend Growth
Cullinan Oncology does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CGEM.

2.5

News and Social Media Coverage

News Sentiment
Cullinan Oncology has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 49 news articles for Cullinan Oncology this week, compared to 2 articles on an average week.
Search Interest
Only 4 people have searched for CGEM on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.
MarketBeat Follows
4 people have added Cullinan Oncology to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cullinan Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,210,800.00 in company stock.
Percentage Held by Insiders
Only 8.82% of the stock of Cullinan Oncology is held by insiders.
Percentage Held by Institutions
86.31% of the stock of Cullinan Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cullinan Oncology are expected to grow in the coming year, from ($3.21) to ($3.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cullinan Oncology is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cullinan Oncology is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cullinan Oncology has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

[Shocking] Elon Musk’s Plan To End Banks

Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.

Click here now to get your copy.

About Cullinan Oncology Stock (NASDAQ:CGEM)

Cullinan Oncology, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CGEM Stock News Headlines

April 21, 2024 | americanbankingnews.com

Cullinan Oncology (NASDAQ:CGEM) Shares Down 3.3%

April 20, 2024 | americanbankingnews.com

Q2 2024 EPS Estimates for Cullinan Oncology, Inc. (NASDAQ:CGEM) Boosted by Analyst

April 23, 2024 | Traders Agency (Ad)

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)

AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.

April 20, 2024 | americanbankingnews.com

Analysts Set Cullinan Oncology, Inc. (NASDAQ:CGEM) Price Target at $27.75